Effects of Surgery Types in Patients With Pulmonary Nodules
Pulmonary Nodule
About this trial
This is an interventional screening trial for Pulmonary Nodule focused on measuring pulmonary nodule, pulmonary function, functional exercise capacity, physical activity, respiratory muscle strength, respiratory muscle endurance, quality of life
Eligibility Criteria
Inclusion Criteria:
- Being between 18-80 years of age,
- Patients with pulmonary nodule who were planned lobectomy surgery with one of VATS or thoracotomy techniques,
- Being able to walk,
Exclusion Criteria:
- Any type of surgery planned except lobectomy,
- Having heart failure or atrial fibrillation,
- Having acute viral infections during all assessment,
- History of acute myocard infarction within last six months,
- Uncontrolled diabetes or hypertension,
- Having orthopedic, neurological and psychological disorders that influence the results of study.
Sites / Locations
- Gazi University, Faculty of Health Science, Department of Physiotherapy and Rehabilitation, Cardiopulmonary Rehabilitation Unit
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Patients with pulmonary nodule scheduled VATS
Patients with pulmonary nodule scheduled thoracotomy
Patients with pulmonary nodule scheduled VATS were included in this study. Inclusion and exclusion criteria were considered. Pulmonary function (spirometry), functional exercise capacity (6-minute walk test (6-MWT); 6-minute stepper test (6-MST)), physical activity level (metabolic holter), respiratory (maximal inspiratory and expiratory pressures (MIP-MEP); mouth pressure device) and peripheral muscle strength (dynamometer), inspiratory muscle endurance (incremental loading test), quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTCQOL)), fatigue (Fatigue Severity Scale), dyspnea perception (Modified Medical Research Council dyspnea scale (MMRC)) and pain severity (Visual Analog Scale) were assessed before VATS and average two weeks after surgery.
Patients with pulmonary nodule scheduled thoracotomy were included in this study. Inclusion and exclusion criteria were considered. Pulmonary function (spirometry), functional exercise capacity (6-minute walk test (6-MWT); 6-minute stepper test (6-MST)), physical activity level (metabolic holter), respiratory (maximal inspiratory and expiratory pressures (MIP-MEP); mouth pressure device) and peripheral muscle strength (dynamometer), inspiratory muscle endurance (incremental loading test), quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTCQOL)), fatigue (Fatigue Severity Scale), dyspnea perception (Modified Medical Research Council dyspnea scale (MMRC)) and pain severity (Visual Analog Scale) were assessed before VATS and average two weeks after surgery.